BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
OPDIVO (nivolumab) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2014.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO (nivolumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1) checkpoint, enabling the immune system to recognize and attack cancer cells. It is approved for multiple oncology indications across melanoma, non-small cell lung cancer, renal cell carcinoma, and other malignancies. The drug works by removing the 'off switch' that tumors use to evade immune surveillance. OPDIVO represents a foundational immunotherapy in the PD-1/PD-L1 inhibitor class and remains a standard-of-care option in numerous treatment algorithms.
$0.1BPart D
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Started Nov 2026
30 enrolled
Untreated MelanomaUnresectable MelanomaMetastatic Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Started Jun 2026
120 enrolled
Melanoma
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
Started May 2026
131 enrolled
Squamous Cell Carcinoma of Head and Neck (SCCHN)
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Started Apr 2026
120 enrolled
Advanced Renal Cell Carcinoma (aRCC)Metastatic Renal Cell Carcinoma ( mRCC)Clear Cell Renal Cell Carcinoma (ccRCC)
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Started Apr 2026
170 enrolled
Advanced Microsatellite Stable Colorectal Cancer
Worked on OPDIVO at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.